Lysyl oxidase like-2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC).
in North America and Europe PSC is estimated to affect as many as 13-16 people per 100,000 population. (1, 2) The incidence and prevalence of PSC appear to be increasing (3, 4) ; however, this may be due to heightened disease awareness and improved diagnostic methods. Up to 80% of patients with PSC have inflammatory bowel disease (IBD). (5, 6) The presentation of PSC and its clinical featuresliver biochemistry, cholestasis, and accompanying IBD-are highly variable and fluctuate over time, depending on phenotype and other unidentified factors. (7) (8) (9) Most patients eventually progress to biliary cirrhosis, but the pace of progression varies greatly. Due to the patchy distribution of fibrosis in PSC, liver biopsy is limited by sampling error. As such, PSC is typically diagnosed based on results of magnetic resonance cholangiopancreatography (MRCP), which has a sensitivity of 86% and specificity of 94%. (10) Noninvasive biomarkers to assess fibrosis severity, monitor disease progression, and evaluate the effect of experimental treatments in clinical trials are needed. To date, no treatments specific for PSC have been approved. Episodes of ascending cholangitis are managed with antibiotics in conjunction with therapeutic biliary drainage as necessary. (11, 12) While ursodeoxycholic acid (UDCA) can improve liver biochemistry, a beneficial impact on clinical outcomes has not been demonstrated. (13) The only effective therapeutic option for PSC is liver transplantation.
Because patients with PSC experience complications due to fibrosis of the liver and biliary tree, therapeutic inhibition of fibrosis could be of benefit. Serum and hepatic levels of the amine oxidase lysyl oxidase-like-2 (LOXL2) are correlated with more severe fibrosis in patients with PSC. (14, 15) LOXL2 catalyzes the crosslinkage of collagen and elastin, thereby mediating stabilization of the fibrotic matrix. (16) Inhibition of LOXL2 reduces progression of liver fibrosis in murine models of nonbiliary and biliary fibrosis. (16, 17) For example, in the multidrug resistance 2 knockout and 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse models of biliary fibrosis, an anti-LOXL2 antibody reduced progression of fibrosis as well as the ductular reaction and hepatic stellate cell activation. (16) Simtuzumab is a humanized monoclonal antibody directed against LOXL2 that has been investigated for its ability to prevent or reverse fibrosis progression in several disease states, including nonalcoholic steatohepatitis (NASH), in which two recent phase 2b trials of patients with bridging fibrosis and cirrhosis were negative. (18) (19) (20) (21) (22) (23) In this randomized, placebo-controlled study, we evaluated the safety and effectiveness of simtuzumab in halting or reversing fibrosis progression in patients with PSC.
Patients and Methods

patieNtS
We enrolled patients between March 4, 2013, and July 23, 2014 , at 61 sites in North America and Europe (32 in the United States; 7 in Canada; 6 in the United Kingdom; 3 each in Germany and Spain; 2 each in Belgium, Denmark, France, and Italy; and 1 each in the Netherlands and Sweden). Patients were aged 18-70 years with chronic cholestatic liver disease (≥6 months) due to PSC as confirmed by liver biopsy and MRCP. All patients had aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤10 times the upper limit of normal. Due to uncertainty regarding the effects of simtuzumab on mucosal healing, the original protocol excluded patients with ulcerative colitis (UC) and a partial Mayo score for the assessment of UC activity of >2. When initial results indicated that this was not a concern, eligibility criteria were modified to exclude patients with a partial Mayo score >4, partial Mayo bleeding score >1, or current use of oral corticosteroids and/or inhibitors of tumor necrosis factor alpha or α4β7 integrin.
Patients with secondary sclerosing cholangitis, primary biliary cholangitis, viral hepatitis, or alcoholic liver disease and any history of hepatic decompensation were excluded. Patients with a history of cholangiocarcinoma, ascending cholangitis within 60 days of screening, or the presence of a percutaneous drain or bile duct stent were also excluded. Additional exclusions are provided in the Supporting Information.
StuDy DeSigN
This was a phase 2b, dose-ranging, randomized, double-blind, and placebo-controlled study. Participants were randomly assigned in a 1:1:1 ratio to 96 weeks of weekly subcutaneous injections with 75 mg simtuzumab, 125 mg simtuzumab, or placebo. Randomization was managed by using an interactive web response system (Bracket, San Francisco, CA). A statistician employed by the sponsor generated the randomization code using the SAS program (SAS Institute, Inc, Cary, NC). Randomization was stratified based on the presence or absence of elevated serum immunoglobulin G4 (IgG4) levels (>140 mg/dL) at baseline. Patients and all personnel directly involved in the study were blinded to treatment assignment.
All patients underwent MRCP, liver biopsy, blood chemistry panel, and serum markers of fibrosis prior to their first dose of study drug. Patients underwent repeat MRCP and liver biopsy at weeks 48 and 96. Serum markers of fibrosis, including the enhanced liver fibrosis (ELF) test (Siemens Healthcare, Erlangen, Germany), FibroSure (LabCorp, Burlington, NC)/ FibroTest (Biopredictive, Paris, France), and serum LOXL2 (VIDAS immunoassay; BioMérieux, Marcy l'Etoile, France), were measured at weeks 4, 8, and 12 and every 12 weeks thereafter. In a subset of patients, liver stiffness was measured by transient elastography (TE; FibroScan; Echosens, Paris, France).
The study protocol was approved by the review board or ethics committee of each institution prior to study initiation. The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines and the Declaration of Helsinki.
liVer HiStology
Core liver biopsies were obtained at screening and at weeks 48 and 96. Biopsies were read by a single central reader (Z.G.) who was blinded to treatment assignment but not biopsy sequence. Histological assessments included the adequacy of the biopsy specimen, confirmation of the diagnosis, morphometric quantification of hepatic collagen content and alpha-smooth muscle actin (α-SMA) expression, and fibrosis staged according to the Ishak classification. For morphometric quantification of hepatic collagen, one biopsy section was stained with picrosirius red. α-SMA, a marker of stellate cell and myofibroblast activation, (24) was identified immunohistochemically (Ventana Benchmark Ultra autostainer using prediluted Dako Clone 1A4 and Ultraview Universal DAB detection kit). For quantification of α-SMA expression and collagen content, a digital image of the entire stained section was acquired using an Aperio ScanScope XT (Leica Biosystems, Vista, CA) at ×20 magnification. To quantify the fraction of positively stained pixels, the Aperio Positive Pixel Count algorithm was used according to the manufacturer's instructions and as described. (25) The results were expressed as the percentage of the entire biopsy section that was positive for the color of interest.
eFFiCaCy eNDpoiNtS aND StatiStiCal aNalySeS primary endpoint and Sample Size
The primary efficacy endpoint was the mean change from baseline in hepatic collagen content measured by morphometry on liver biopsy specimens at week 96 in all patients who were randomized and treated. This change was assessed as a least squares mean estimate of the difference in mean hepatic collagen at week 96 versus baseline based on a mixed-effect model including treatment group, visit, treatment by visit interaction, baseline hepatic collagen, and presence or absence of elevated serum IgG4 at baseline as fixed effects. Subgroup analyses of changes in hepatic collagen were conducted according to baseline serum levels of IgG4 (≤ versus >140 mg/dL) and LOXL2 (≤ versus > the median), both prespecified, and advanced fibrosis (Ishak stage 0-2 versus 3-6).
The sample size was based on the assumption that over 96 weeks the placebo arm would experience a mean relative increase in hepatic collagen of approximately 30% (absolute increase of approximately 3%) (25) and that simtuzumab treatment would lead to a 1% absolute reduction in collagen formation. (17) Based on these assumptions, we calculated that 58 patients per treatment group would yield 90% power to detect a 4% difference between treatment groups in mean change from baseline in hepatic collagen content. We assumed a dropout rate between 20% and 25%. Based on the midpoint of this range (22.5%), a sample size of 75 patients per arm was planned (see Supporting Information for details of the statistical analysis).
Secondary endpoints
A secondary efficacy endpoint was prevention of progression of fibrosis as assessed by change from baseline in Ishak fibrosis stage. A Cochran-MantelHaenszel (CMH) test was used to compare categorized changes in fibrosis from baseline (improved, no change, worse) between simtuzumab 75 mg or 125 mg and placebo stratified by baseline serum IgG4 level. We also assessed predictors of progression to cirrhosis in patients without cirrhosis at baseline (Ishak stages 0-4) using logistic regression analyses. Finally, the occurrence of PSC-related progression events including ascites, spontaneous bacterial peritonitis, variceal hemorrhage, hepatic encephalopathy, ascending cholangitis, cholangiocarcinoma, hepatocellular carcinoma, liver transplantation, and death was assessed. Cases of ascending cholangitis were adjudicated by a single blinded reviewer (A.J.M.) based on the Tokyo classification. (26) The proportions of patients with PSC-related progression events through week 96 were compared using a CMH test stratified by baseline serum IgG4 level. We also performed Cox proportional hazards regression analysis using a stepwise procedure to identify independent predictors of time to first PSC-related clinical event. Discrimination of specific markers for clinical events was determined using c-statistics. Optimal thresholds for these markers were determined based on the maximal sum of specificity and sensitivity.
Results
patieNt populatioN
Of the 298 patients who were screened, 235 were randomized and 234 initiated treatment (reasons for screen failure are provided in Supporting Table S1 ). Demographic and baseline characteristics were similar between the treatment groups (Table 1) . Overall, the median age of patients was 45 years (interquartile range [IQR], 37-52), 64% were male, and 86% were white. Three quarters of patients (76%) had evidence of both intrahepatic and extrahepatic duct involvement on MRCP. UC was reported in approximately half of patients (48%), 62% were treated with UDCA, and 15% had elevated serum IgG4. Median (IQR) alkaline phosphatase (ALP) and bilirubin at baseline were 260 U/L (129-401) and 0.7 mg/dL (0.5-1.1), respectively. Forty percent of patients had bridging fibrosis, and 11% had cirrhosis. At baseline, median (IQR) hepatic collagen content was 4.4% (2.7-7.0), α-SMA expression was 2.5% (1.3-5.6), serum LOXL2 was 103 pg/mL (71-146), ELF was 9.46 (8.60-10.43), and FibroSure/FibroTest was 0.41 (0.23-0.60). All of these measures were significantly correlated with each other (Supporting Table S2 ) and Ishak fibrosis stage at baseline (r = 0.48-0.59; all Continuous data are median (IQR). *Mayo risk score for assessment of prognosis in PSC-related prognosis.
P < 0.001; Supporting Fig. S1a-e) . Liver stiffness measurement (LSM) by TE was available for a subset of patients (n = 58). Liver stiffness correlated with fibrosis stage (Supporting Fig. S2 ), hepatic collagen content, α-SMA expression, and serum fibrosis markers including the ELF test (r = 0.41-0.73; all P < 0.001; Supporting Table S2 ). A liver stiffness value of <14.4 kPa excluded cirrhosis with 100% negative predictive value (Supporting Table S3 ). Eighty-three percent of patients (194/234) completed study treatment (Supporting Fig. S3 ). We report below results from week 96 of this study.
HepatiC CollageN CoNteNt
Patients receiving simtuzumab did not have statistically significant improvement in hepatic collagen content compared with placebo. At week 96, the mean change from baseline (SD) in hepatic collagen content was -0.5% (5.78) for patients receiving simtuzumab 75 mg, +0.5% (6.94) for patients receiving simtuzumab 125 mg, and 0.0 (4.76) for patients receiving placebo (Fig. 1 ). The differences in least squares mean change in hepatic collagen content in patients receiving placebo compared with simtuzumab 75 mg (−0.4; 95% confidence interval [CI], −2.3 to 1.6; P = 0.73) and those receiving simtuzumab 125 mg (1.0; 95% CI, −1.0 to 3.0; P = 0.33) were not significant. In subgroup analyses according to baseline serum LOXL2, serum IgG4, and fibrosis stage, changes in hepatic collagen content did not favor simtuzumab treatment over placebo (Supporting Fig. S4) .
Overall, the median change in hepatic collagen content over 96 weeks for all patients was -1% (IQR, -3.0 to 0.9). Changes in hepatic collagen content did not significantly differ according to baseline UDCA use, IgG4 status (≤140 versus >140 mg/dL), or presence or absence of UC (Supporting Table S4 ).
FiBroSiS Stage
Simtuzumab treatment for 96 weeks did not result in statistically significant improvements in Ishak fibrosis stage (Fig. 2) . Improvement in fibrosis by ≥1 stage was seen in 22% of patients receiving placebo, 32% of patients receiving 75 mg simtuzumab (P = 0.12 versus placebo), and 31% of patients receiving 125 mg simtuzumab (P = 0.13 versus placebo). Overall, 62 patients (29%) had any improvement in fibrosis, including 17 patients (8%) with ≥2-stage improvement (Table 2) . Fibrosis improvement was more common in the simtuzumab-treated groups among patients with elevated serum IgG4 (>140 mg/dL) at baseline (placebo, 10% [1/10] ; simtuzumab 75 mg, 45% [5/11; P = 0.040 versus placebo]; and simtuzumab 125 mg, 44% [4/9; P = 0.036]); however, the number of patients in this analysis was limited. Among patients without cirrhosis at baseline, simtuzumab did not have a statistically significant effect on progression to cirrhosis, which was observed in 18% of patients receiving placebo, 14% receiving 75 mg simtuzumab (P = 0.52), and 15% receiving 125 mg simtuzumab (P = 0.60).
Overall, 80 patients (37%) had worsening of fibrosis (Table 2) . Change from baseline to week 96 in Ishak fibrosis stage in all patients did not significantly differ among patients according to baseline UDCA use, IgG4 status (≤140 versus >140 mg/dL), or presence or absence of UC (Supporting Table S5 ). In univariate analysis, higher baseline ELF (odds ratio [OR], 2.71; 95% CI, 1.80-4.07; P < 0.001), greater change in ELF at week 12 (OR, 3.04; 95% CI, 1.27-7.28; P = 0.012), and higher baseline ALP (OR per 10 U/L, 1.016; 95% CI, 1.000-1.031; P = 0.046) were associated with progression to cirrhosis. The proportion of patients progressing to cirrhosis from baseline to week 96 did not significantly differ according to baseline UDCA use or IgG4 status; however, patients with UC at baseline were less likely to progress to cirrhosis (Supporting Table S6 ). In multivariate analysis, only baseline ELF score (OR, 2.31; 95% CI, 1.52-3.51; P < 0.001) and bridging fibrosis (Ishak stage 3-4 versus 0-2; OR, 4.06; 95% CI, 1.46-11.25; P = 0.007) were associated with progression to cirrhosis.
pSC-relateD CliNiCal eVeNtS
Compared with placebo, neither dose of simtuzumab led to a significant reduction in frequency of PSC-related clinical events (Table 3) . Over a median follow-up of 23.0 months (range, 3.7-27.8), at least one PSC progression event was experienced by 17 patients (22%) receiving 75 mg simtuzumab (P = 0.70 versus placebo), 15 (19%) receiving 125 mg simtuzumab (P = 0.97 versus placebo), and 15 (19%) receiving placebo (Fig. 3) . Overall, 47 patients (20%) experienced at least one PSC-related clinical event. The most common events were cholangitis (13%; n = 31) and evidence of hepatic decompensation (9%; n = 21); 3 patients developed cholangiocarcinoma (1%).
In an exploratory univariate time-to-event analysis, baseline levels of ALP, AST, ALT, gammaglutamyltransferase (GGT), bilirubin, albumin, Model for End-Stage Liver Disease (MELD), ELF score, FibroSure/FibroTest, serum LOXL2, and the presence of bridging fibrosis or cirrhosis (Fig. 4) were significantly associated with the occurrence of PSCrelated clinical events (Supporting Table S7 ). In multivariate analysis, baseline ALP (hazard ratio [HR] per 10 U/L, 1.01; 95% CI, 1.00-1.02; P = 0.015) and the presence of advanced fibrosis (HR, 2.03; 95% CI, 1.02-4.06; P = 0.045) were significantly associated with PSC-related events; ELF score was of borderline significance (HR per unit, 1.26; 95% CI, 0.98-1.61; P = 0.073). In separate univariate/multivariate analyses, baseline ALP and advanced fibrosis were significantly associated with risk of cholangitis and cholangiocarcinoma (Supporting Table S7 ), and baseline ALP, MELD score, and platelet count were significantly associated with fibrosis-related events (Supporting Table S9 ).
association Between Serum alp and pSC-related Complications
Survival free of PSC-related complications according to tertiles of ALP at baseline is shown in Fig. 5A . 3 (4) 6 (8) 1 (1) 4 (6) 4 (6) 10 (13) 10 (14) 8 (11) 20 (9) 17 (8) 18 (8) Stage 1 10 (13) 21 (28) 17 (22) 14 (18) 13 (20) 14 (21) 16 (21) 11 (15) 13 (18) 40 (17) 45 (21) 44 (20) Stage 2 20 (25) 13 (17) 17 (22) 18 (23) 10 (15) 14 (21) 17 (22) 14 (20) 11 (15) 55 (24) 37 (17) 42 (19) Stage 3 20 (25) 18 (24) 17 (22) 21 (27) 21 (32) 14 (21) 16 (21) 11 (16) 12 (17) 57 (24) 50 (24) 43 (20) Stage 4 13 (16) 8 (11) 6 (8) 17 (22) 5 (8) 7 (10) 7 (9) 7 (10) 6 (8) 37 (16) 20 (9) 19 (9) Stage 5 2 (3) 3 (4) 6 (8) 3 (4) 7 (11) 5 (8) 5 (6) 9 (13) 13 (18) 10 (4) 19 (9) 24 (11) Stage 6 5 (6) 9 (12) 8 (10) 3 (4) 6 (9) 9 (13) 7 (9) 9 (13) 9 (13) 15 (6) 24 (11) 26 (12) Worsening, n (%) The optimal threshold for change in ELF at week 12 to predict events was ≥0.19 (sensitivity 69%, specificity 62%). Whereas 26% (24/94) of patients with a change in ELF ≥0.19 experienced an event, only 9% (11/125) of those with lesser change had an event (HR after adjustment for baseline ELF, 4.02; 95% CI, 1.95-8.32; P < 0.001) (Fig. 5C ). Changes in ELF at weeks 24 and 36, but not week 48, were also predictive of clinical events after adjustment for baseline ELF (data not shown). The c-statistic for baseline ELF to predict clinical events was similar to that of Ishak stage (0.71, 95% CI, 0.63-0.79, versus 0.69, 95% CI 0.61-0.77; P = 0.69); this improved to 0.78 (95% CI, 0.71-0.86) by adding change in ELF at week 12. ELF at baseline (OR, 3.00; 95% CI, 1.97-4.57; P < 0.001) and greater change at week 12 (OR, 3.04; 95% CI, 1.27-7.28; P = 0.012) were also associated with progression to cirrhosis.
association Between liver Stiffness by te and pSC-related Complications
In the subset of patients with TE assessments, baseline values of liver stiffness were a significant predictor of PSC-related events (HR, 1.03 per kPa; All PSC progression events, n (%)* 17 (22) 15 (19) 15 (19) 47 (20) Ascending cholangitis 13 (16) 11 (14) 7 (9) 31 (13) Jaundice 6 (8) 5 (6) 4 (5) 15 (6) Ascites 3 (4) 3 (4) 1 (1) 7 (3)
Hepatic encephalopathy 0
*Represents total number of patients with at least one PSC-related clinical event. Numbers of specific events are greater than the total as individual patients may have more than one kind of event. 95% CI, 1.003-1.057; P = 0.026). After adjustment for liver stiffness at baseline, changes in LSM between baseline and week 48 were not associated with clinical events. The c-statistic for liver stiffness at baseline to predict clinical events was 0.74 (95% CI 0.58-0.89), nonsignificantly higher than baseline Ishak fibrosis stage (0.67; 95% CI, 0.51-0.83; P = 0.31). The optimal threshold for LSM to predict clinical events was >8.7 kPa (sensitivity 79%, specificity 59%) (Supporting Fig. S5 ). 
SaFety
The number and types of adverse events were similar between treatment groups (Supporting Table S4 ). Four patients had serious adverse events that were considered treatment-related by the investigator and led to treatment discontinuation. One patient each had ventricular tachycardia, benign biliary neoplasm (both on 75 mg simtuzumab), colitis, and elevated liver transaminases (both on 125 mg simtuzumab). Adverse events leading to premature discontinuation of study drug occurred in 5% of patients receiving simtuzumab 75 mg, 8% of patients receiving simtuzumab 125 mg, and 10% of patients receiving placebo (Supporting Table S10 ). The only adverse event that led to discontinuation of study drug in more than 1 patient was cholangiocarcinoma (2 patients in the placebo group).
Nearly all (>98%) patients experienced treatment-emergent laboratory abnormalities (Supporting Table S11 ). Grade 3 or 4 abnormalities were reported for 60% of patients receiving simtuzumab 125 mg, 59% of those receiving simtuzumab 75 mg, and 56% of those receiving placebo. The most common grade 3 or 4 abnormalities in any treatment group were elevated liver biochemistry (AST in 21%, ALT in 19%, and GGT in 17%).
Of the 112 patients with UC at baseline, 7 (1%) experienced UC-related adverse events during treatment: 2 on simtuzumab 125 mg, 1 on simtuzumab 75 mg, and 5 on placebo. One of these events was grade 3 in severity, and the others were grade 1 or 2. One patient, who received placebo, developed new-onset UC during treatment.
Discussion
In this phase 2b, dose-ranging, randomized, double-blind, placebo-controlled study, 96 weeks of treatment with the LOX2 inhibitor simtuzumab provided no significant benefit in clinical, histologic, or biochemical endpoints in patients with PSC. Although simtuzumab was ineffective, the detailed longitudinal data collected from this large, well-characterized population represent a valuable resource for better understanding the natural history of PSC disease over a 2-year period. These data will help to inform the design of future trials, especially those with histological endpoints.
Over the 2 years of our study, 20% of the 234 patients had PSC-related clinical events including hepatic decompensation, ascending cholangitis, and cholangiocarcinoma. The most common complication was ascending cholangitis, which was experienced by 31 patients (12%). Epidemiologic data regarding ascending cholangitis in patients with PSC are limited. However, in a retrospective cohort study of 171 patients with PSC on the waiting list for liver transplantation at an academic transplant center, 28% had an event of cholangitis over 10 years. (27) Cholangiocarcinoma is another hallmark clinical event related to PSC. The 3% incidence of cholangiocarcinoma we observed over 2 years is consistent with the annual incidence of 0.5%-1% reported in a large population-based study conducted in the Netherlands. (28) In this study, important predictors of progression to cirrhosis or the occurrence of clinical events included serum ALP, the ELF score, and the presence of advanced fibrosis on liver biopsy at baseline. An ALP cutoff of 1.5 times the upper limit of normal (>220 U/L) has been associated with clinical outcomes in PSC 1 or 2 years after the diagnosis.
(7) Our study showed a significant stepwise increase in risk of clinical events at week 96 from 6% in patients with baseline ALP <158 U/L (just above the upper limit of normal) to 19% in patients with ALP between 158 and 324 U/L to 34% in patients with ALP >324 U/L (Fig. 5A ). These data suggest that baseline ALP may be a useful stratification factor in clinical trials. However, change in ALP at week 12 (or later time points, data not shown) was not associated with clinical events. Although this may be due to the minimal variability in ALP observed during the study, data regarding the prognostic impact of changes in ALP are contradictory. Whereas patients treated in the very high-dose UDCA study had significantly greater improvement in ALP than patients treated with placebo, an increased risk of complications was observed in UDCA-treated patients. (29) In contrast, in the Scandinavian high-dose UDCA study, patients with at least a 40% reduction or normalization of ALP, regardless of treatment assignment, had improved survival, (30) suggesting that change in ALP cannot yet be considered sufficient for use as a surrogate endpoint-at least in isolation-for liver-related complications in clinical trials of patients with PSC.
As expected, PSC patients with advanced fibrosis had a 2-fold risk of complications compared with patients with no to moderate fibrosis. In keeping with these findings, noninvasive markers of fibrosisnamely LSM by TE and the ELF test-were associated with PSC-related complications. For example, patients with a liver stiffness ≥8.7 kPa by TE had an approximately 6-fold risk of clinical events. Corpechot and colleagues reported similar findings in a study evaluating the prognostic significance of LSM by TE in 168 PSC patients followed for at least 1 year. (31) Interestingly, change in LSM was significant in the Corpechot et al. study but not our own, potentially due to the small size of our cohort with TE data. We also observed a significant association between the ELF test-both at baseline and its change over 12 weeks-and the occurrence of clinical events. After adjustment for serum ALP and fibrosis stage, baseline ELF score was of borderline prognostic significance, suggesting that it might be useful in addition to these tools to refine risk stratification among patients with PSC. Moreover, our data suggest that change in ELF has potential as a surrogate marker of treatment efficacy for use in clinical trials.
In this study, the antifibrotic effects of simtuzumab were evaluated based on changes in hepatic collagen content and fibrosis stage on liver biopsy. Over 2 years, changes in collagen content were modest; a median reduction of 1% was observed in the entire cohort. Roughly one third of patients had fibrosis improvement, one third remained stable, and one third had fibrosis progression. These data likely reflect sampling variability of liver biopsy due to the patchy distribution of liver fibrosis in PSC. Our findings have important implications for the design of future trials that include histological assessment of fibrosis as an endpoint. The data also underscore the commitment and willingness of patients with PSC to undergo serial liver biopsies in the clinical trial setting, likely due to the lack of treatment options in this condition.
The failure of simtuzumab in this study, as in two large trials of patients with NASH and advanced fibrosis, (32) may be due to a number of factors. First, correlations between serum LOXL2 levels and liver fibrosis observed in PSC and other conditions may not represent a causal relationship. Second, the activity of simtuzumab may be insufficient to inhibit collagen crosslinkage in vivo and thereby exert an antifibrotic effect. This possibility is difficult to confirm because a pharmacodynamic marker of LOXL2 inhibition is not available. Third, LOXL2 inhibition may be ineffective due to redundancy in other pathways that mediate collagen crosslinkage (e.g., other LOX isoforms and tissue transglutaminase). (33) Finally, hepatic fibrosis in the study population as a whole, and within tight biliary strictures specifically, may have been too advanced to be amenable to the proposed mechanism of action of simtuzumab.
Our study has several strengths including its large number of well-characterized PSC patients, longitudinal assessment of liver histology, and the observation of a sufficient number of clinical events to evaluate prognostic markers in PSC. However, our study also has limitations. First, we included only patients with classic large-duct PSC. The generalizability of our findings to other populations including patients with small-duct PSC, IgG4-related sclerosing cholangitis, and children is unclear. Moreover, our study cohort had a lower prevalence of IBD than the broader PSC population, and all patients with IBD had quiescent disease. Although recent data suggest that patients with PSC and UC have a higher risk of liver disease progression than those with Crohn's disease or no IBD, (6) our data suggest that patients with UC were less likely to progress to cirrhosis. However, because the presence of UC did not impact changes in hepatic collagen content or fibrosis stage per se, these findings require confirmation in larger studies.
One of the key challenges in developing novel agents for the treatment of patients with PSC is selection of appropriate surrogate endpoints. (34) The main outcomes of interest-death, end-stage liver failure, and cholangiocarcinoma-occur too infrequently to serve as primary endpoints in clinical trials, and obtaining adequate data for statistical inference would require a prohibitively large sample size, especially in a rare disease like PSC. Potential surrogate endpoints that require additional validation include patient-reported outcome measures, cholangiographic findings, liver stiffness (by TE or magnetic resonance elastography), and other exploratory biomarkers. (35) We have recently described the prognostic significance of qualitative MRCP findings based on data collected in the current study. (36) In conclusion, this phase 2b trial indicates that simtuzumab is ineffective at reducing fibrosis or preventing clinical complications in patients with PSC. However, the results of this study-one of the largest prospective studies ever undertaken in patients with PSC-yield important insights into the natural history of disease and the utility of noninvasive markers that will inform the design of future clinical trials and the development of other investigational compounds for the treatment of this disease.
